Results from an international study challenge current practice of screening for ovarian cancer relapse. 

"/>
ADVERTISEMENT

CA-125 Monitoring Not Helpful for Ovarian Cancer Survivors

Results from an international study challenge current practice of screening for ovarian cancer relapse. 

BY ELIZABETH WHITTINGTON
PUBLISHED SATURDAY, JUNE 6, 2009
Talk about this article with other patients, caregivers, and advocates in the Ovarian CURE discussion group.
Results from an international study challenge current practice of screening for ovarian cancer relapse. Currently, survivors undergo quarterly monitoring of CA-125, a protein that is predictive of ovarian cancer relapse. With early detection of recurrence, patients often begin treatment before symptoms manifest. However, a study showing that early treatment does not improve overall survival may change that tradition.  

The study looked at 529 ovarian cancer survivors who were in remission but whose CA-125 levels began to rise. Researchers found that the group who received treatment at the time their levels increased did not live longer than the group who received treatment after the onset of symptoms (these patients did not have their levels made available to the physician or patient). Patients with early treatment received therapy about four to five months sooner than the delayed treatment group, but this did not result in improved survival. In addition, the quality of life was lower in the group who received quarterly CA-125 testing, presumably because of anxiety about the results and because this group was exposed to more types of chemotherapy and longer treatment.

“For the first time, women can be offered informed choices after first-line chemotherapy,” said presenter Gordon Rustin, MD, of Mount Vernon Cancer Centre, during the presentation. Because early treatment does not result in a survival advantage or a longer remission, Rustin told doctors there is no benefit from early recurrence detection with routine CA-125 testing. 

Talk about this article with other patients, caregivers, and advocates in the Ovarian CURE discussion group.
ADVERTISEMENT
ShareYourStory
Related Articles
For Best Survival in Ovarian Cancer, Chemotherapy Doses Must be in Line with Body Weight
BY LAUREN M. GREEN
According to professional practice guidelines, women with ovarian cancer should get doses of chemotherapy that are based on their weight. When they receive less than that, a new study has found, the result can be poorer survival.
CURE Magazine Teams Up with the Foundation for Women's Cancer in Advocacy Spotlight Partnership Program
CURE Magazine and the Foundation for Women's Cancer have teamed up in CURE's Advocacy Spotlight Partnership program to battle women's cancer through education and shared advocacy on behalf of women suffering from below-the-belt women's cancers.
An Expedition Through Cancer
Backpacking through Nepal, two magicians discover a life-changing secret.
Rucaparib Elicits High Response Rate in BRCA-Mutant Ovarian Cancer
BY SILAS INMAN
Treatment with a new PARP inhibitor called rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer.
Two-Pronged Strategy With Lynparza Gains Traction in Breast and Ovarian Cancers
BY ANITA T. SHAFFER
A two-pronged strategy combining the PARP inhibitor Lynparza and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with TNBC and for patients with high-grade serous ovarian cancer.
Related Videos
Adele Croteau Discusses the Impact of Her Mother’s Cancer
BY ADELE CROTEAU
We sat down with Adele Croteau, a survivor of cervical cancer from Ottawa, Canada, at I Had Cancer's "A Celebration of Shared Experiences Honoring You."
Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers
When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.
$auto_registration$